Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
GI Oncology Now
Bile Duct Cancer
Colorectal Cancer
Gastroesophageal Cancer
Gastric Cancer
GEP-NETs
GIST
Liver Cancer
Pancreatic Cancer
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Andrew Moreno
Editor
Articles by Andrew Moreno
Study of Women with SCD Suggests C-Reactive Protein Level Link to Menstrual Cycle
Andrew Moreno
Sickle Cell Disease
|
April 29, 2025
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Read More
How Is Machine Learning Augmenting Decision Making in Myelofibrosis Care?
Adrián Mosquera Orgueira, MD, PhD
Myelofibrosis
|
April 25, 2025
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
View More
Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance
Andrew Moreno
Hemophilia
|
April 23, 2025
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
Read More
Study: Differences in Malignant Hematologic Neoplasm Cytokine Storm Etiology Have Clinically Meaningful Effects
Andrew Moreno
Hematology
|
April 21, 2025
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
Read More
Novel Cell Therapy Product for Bone Marrow Failure Syndromes Receives FDA Aplastic Anemia Orphan Drug Designation
Andrew Moreno
Anemia
|
April 15, 2025
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Read More
Reduced-Dose Apixaban Anticoagulation Noninferior to Full Dose in Prevention of Cancer-Associated VTE
Andrew Moreno
VTE
|
April 15, 2025
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Read More
Biotechnology Company Grants Commercial License for Cell Manufacturing Platform Use to Advance SCD Therapy
Andrew Moreno
Sickle Cell Disease
|
April 8, 2025
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
Read More
ASH Bridge Grant Expands Award Eligibility to Advance Hematology Research
Ivan Maillard, MD, PhD
Hematology
|
April 8, 2025
ASH Awards Commitee Chair Ivan Maillard, MD, PhD, and prior awardee Rinku Majumder, PhD, tell of the Grant's positive impact.
View More
FDA Grants Orphan Drug Designation for MDS to Investigational CLEVER-1-Targeting Immunotherapy
Andrew Moreno
MDS
|
April 2, 2025
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Read More
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
Andrew Moreno
MDS
|
March 31, 2025
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
Read More
Novel CAR T-Cell Therapy for Relapsed Refractory DLBCL Receives FDA Fast Track Designation
Andrew Moreno
Hematology
|
March 26, 2025
Azercabtagene zapreleucel is an allogeneic CD-19-targeting therapy combining lymphodepletion chemotherapy with interleukin-2.
Read More
Injectable Rusfertide Shows Promise for Erythrocytosis Control in Phlebotomy-Dependent PV
Andrew Moreno
Polycythemia Vera
|
March 25, 2025
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Read More
Pulmonary Hypertension Risk in PV: How Does Its Presence Impact Patient Survival?
Andrew Moreno
Polycythemia Vera
|
March 19, 2025
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
Read More
Phase 2 Data Available: Spleen Tyrosine Kinase Inhibitor for Warm Autoimmune Hemolytic Anemia
Andrew Moreno
Anemia
|
March 18, 2025
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
Read More
Trial Launched of SQ Monovalent Human Antibody Prophylaxis for All Types of Von Willebrand Disease
Andrew Moreno
von Willebrand Disease
|
March 17, 2025
The first-in-class agent operates by increasing both von Willebrand factor and factor VIII levels in patients.
Read More
ASH 2024 Presentations Reveal Recent Advances in Thrombocytopenia Knowledge
Andrew Moreno
Thrombocytopenia
|
March 14, 2025
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
Read More
Study Assesses Prevalence of Thrombotic Events, Impact on Survival in Patients With New Diagnosis of MM
Andrew Moreno
Thrombosis
|
March 12, 2025
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
Read More
Commercialization Approval Granted to Selinexor for Multiple Myeloma, DLBCL in Indonesia
Andrew Moreno
Hematology
|
March 10, 2025
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
Read More
Experts Discuss: Tyrosine Kinase Inhibitors in Systemic Mastocytosis, JAK Inhibitors in Myelofibrosis
Andrew Moreno
Myelofibrosis
|
March 6, 2025
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Read More
Experts Discuss New Data on Roles of CAR T Cells, Bispecific Antibodies, and Novel Therapies in NHL Care
Andrew Moreno
Hematology
|
March 5, 2025
Neil Love, MD, has moderated an expert panel discussing current practice and recent data behind these treatments for NHL.
Read More
Load More